J.P. Morgan analyst James Gordon has maintained their bullish stance on AZN stock, giving a Buy rating on September 20. James Gordon has given his Buy rating due to a combination of factors ...
The most recent trading session ended with Astrazeneca (AZN) standing at $78.38, reflecting a -0.66% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's ...